IIBR-100
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Other names | Brilife |
Routes of administration | Intramuscular |
Part of a series on the |
COVID-19 pandemic |
---|
|
|
|
|
COVID-19 portal |
IIBR-100 also known as Brilife is a COVID-19 vaccine candidate developed by The Israel Institute for Biological Research.[1][2]
References[edit]
- ^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
- ^ Jeffay N (29 December 2020). "As Israel goes vaccine-wild, will the homegrown version lose its shot?". The Times of Israel. Retrieved 1 January 2021.
External links[edit]
Scholia has a profile for Brilife (Q100694835). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=IIBR-100&oldid=1020863339"
Hidden categories:
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from April 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles